Program
The scientific program of the workshop is now available. Please use the link at the right side of this page to download the program >>>>>>>
This version of the program might not be the final version as adjustements might occur.
Confirmed Invited Speakers
-
E. Acosta: Dose-Response Curves and Inhibitory Potential of ARV
Dr. Edward Acosta, Pharm MD Associate professor University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA. The long-term goals of Dr. Acosta's laboratory is to optimize antiviral dosing strategies in adult and pediatric patients through integration of pharmacokinetic, pharmacodynamic, virologic, and pharmacogenetic data ...
Read more
-
T. Arien: NanoTechnology - the Promises and Challenges for Antiretroviral Therapy
Albertina Ariën PhD is Principal Scientist in Pharmaceutical Development at Johnson and Johnson Pharmaceutical R&D in Beerse, Belgium. Her expertise is in the area of liquid formulation development for oral and parenteral applications. She started working at J&J in 1998 after a 2-year post-doctoral training at the University of Nottingham. In 1995 she received her PhD in Biomedical Sciences ...
Read more
-
R. Bertz: Microdosing
Dr. Rick Bertz is currently a Group Director for Virology and Neurosciences in Clinical Pharmacology at Bristol-Myers Squibb. He received a BS in Pharmacy from the University of Wisconsin and a PhD in Pharmaco-kinetics/Pharmacodynamics from the University of Pittsburgh. During his 14 year career in pharmaceutical industry, Rick has been involved in all phases of clinical drug development ...
Read more
-
C. Csajka: Incorporating Pharmacogenetics into Population PK Modeling
Dr. Chantal Csajka, PhD Clinical Pharmacology and Toxicology of the University Hospital Center of the Canton of Vaud and as senior scientist of the department of pharmaceutical Sciences of the University of Geneva and Lausanne in Switzerland. Dr. Csajka’s field of interest is population pharmacokinetic modeling of pharmaceutical agents. Her recent and main current research includes investigations on antiretroviral drugs ...
Read more
-
C. Flexner: Pharmacology of Aging
Charles W. Flexner, M.D is Professor of Medicine in the Divisions of Clinical Pharmacology and Infectious Diseases, and Professor of Pharmacology and Molecular Sciences in the Johns Hopkins University School of Medicine. He is also Professor of International Health in the Johns Hopkins University Bloomberg School of Public Health. Dr. Flexner is Associate Vice-Chair for ...
Read more
-
J. Gerber: Evolution of Clinical Pharmacology of HIV Therapy
Dr. John G. Gerber, MD is a Professor of Medicine and Pharmacology at the University of Colorado Health Sciences Center in the divisions of Infectious Diseases and Clinical Pharmacology. He is board certified in Internal Medicine and Infectious Diseases. He recently retired from the University of Colorado Health Sciences Center after 28 years on the faculty. He presently consults for several pharmaceutical companies ...
Read more
-
C. Hendrix: Prevention of HIV Transmission -PrEP
Dr. Craig Hendrix is an associate Professor of Medicine, Pharmacology, and Epidemiology at Johns Hopkins University where he is the Director of the Drug Development Unit which focuses on early phases of antiviral drug development. He has 19 years of post-fellowship experience as principal investigator of clinical research studies, primarily studying the pharmacokinetics and pharmacodynamics of new drugs for HIV infection. ...
Read more
-
S. Khoo: Challenges with Malaria coinfection
Dr. Saye Khoo is a Reader in Pharmacology at the University of Liverpool and Honorary Consultant Physician in Infectious Diseases. Dr. Khoo chairs the Mersey, Cheshire & N Wales HIV Managed Care Network, and is actively involved in service development through the Mersey & Cheshire Sexual Health Network, and the Regional Sexual Health Task Group for NW England. ...
Read more
-
D. Margolis: Curing HIV: pharmacologic approaches to target latency
Dr. David M. Margolis is a professor of Medicine, Microbiology & Immunology, and Epidemiology at the University of North Carolina at Chapel Hill. He is a member of the American Society of Clinical Investigation, and a fellow of the American College of Physicians and the Infectious Diseases Society of America. Dr. Margolis' laboratory studies molecular ...
Read more
-
J. Morris: Challenges in Pediatic Formulations and Dose Selection
Dr. John B. Morris is a CMC Project Scientific Director at Abbott Laboratories. He leads drug product development activities from Discovery to commercialization for cross-functional teams of formulators, analysts, process engineers and other specialties representing the various areas of expertise. Responsibilities include all technical activities relating to chemistry, manufacturing, and control (CMC) during the development ...
Read more
-
K. Reynolds: FDA experiences with drug development for pediatric patients
Dr. Kellie Reynolds is deputy director of the Division of Clinical Pharmacology 4 in the Office of Clinical Pharmacology, Center for Drug Evaluation and Research, FDA. Dr. Reynolds received her B.S. in Biochemistry from Virginia Tech and her Pharm.D. from Virginia Commonwealth University. She completed a fellowship in Clinical Pharmacokinetics and Drug ...
Read more
-
E. Rook: EMEA position on Pediatric Formulation and Dose selections
Dr Elisabeth J. Rook, MD PhD, epidemiologist, has been employed as a Senior Clinical Assessor at the Dutch Medicine Evaluation Board (MEB) since 2004. The MEB has a top-5 position in participating in centralized procedures as Rapporteur for other member states. The main focus of her daily work is the assessment of Pharmacokinetic & Pharmacodynamic data from registration dossiers of both new and registered ...
Read more
-
S. Taylor: Clinical Cases Presentations
Dr. Steve Taylor, MBChB, FRCP, PhD is a Consultant Physician in HIV and GU Medicine at Birmingham Heartlands Hospital, and an Honorary Senior Clinical Lecturer at the University of Birmingham.He has been the Lead Consultant for the Heartlands HIV Service since 2004. He was elected to the BHIVA Executive Committee in 2003 and currently sits on the Scientific Committees for the International ...
Read more
-
M. Boffito: Clinical Case Presentations
Dr. Marta Boffito is a Consultant in HIV Medicine and Clinical Lead for Clinical Trails at Chelsea and Westminster Hospital, London, UK, where, in addition to her clinical duties, she is heavily involved in numerous clinical studies. Dr Marta Boffito graduated from the University of Turin, Turin, Italy in Medicine in 1996 ...
Read more
